How much is the medical insurance reimbursement price for a box of brigatinib?

Brigatinib (Brigatinib) is a second-generation tyrosine kinase inhibitor used to treat ALK (anaplastic lymphoma kinase)-positive non-small cell lung cancer (NSCLC). This drug is manufactured byAriad Pharmaceuticals developed it and received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2017 for the treatment of ALKpositive NSCLC patients who develop disease progression or are intolerant after treatment with crizotinib (Crizotinib ).

Brigatinib is now available in China and included in the medical insurance catalog. Patients can purchase it domestically at a price of about four to five thousand yuan. For specific prices and medical insurance reimbursement details, it is recommended to consult your local hospital or pharmacy. In comparison, the prices of generic drugs in foreign markets are relatively low, especially those in Laos. The price is only about a few hundred yuan, which is far lower than the domestic price, and the ingredients of the drugs are basically the same.

Brigatinib's mechanism of action is to prevent the growth and spread of cancer cells by inhibiting the activity of ALK tyrosine kinase. Compared with the first-generation ALK inhibitor crizotinib, brigatinib (brigatinib) is effective against multiple ALK mutants such as L1196M, G1269A, etc.) have a stronger inhibitory effect. At the same time, it can effectively cross the blood-brain barrier and have significant curative effect on brain metastases.

Clinical trials have shown that brigatinib has demonstrated excellent efficacy in the treatment of crizotinib-resistant ALKpositiveNSCLC patients. In the ALTA-1L III phase clinical trial, brigatinib (brigatinib) not only significantly prolonged the patients’ progression-free survival (PFS), but also significantly prolonged overall survival (OS) and objective response rate (ORR) shows obvious advantages. These trial results make brigatinib one of the first- and second-line options for the treatment ofALKpositiveNSCLC.

Brigatinib is usually administered orally once daily at an initial dose of 90 mg, increasing to 180 mg after 7 days. AlthoughBrigatinib shows good efficacy and tolerability during treatment, it is also associated with some side effects. Common side effects include nausea, vomiting, diarrhea, cough, headache and fatigue. More serious adverse reactions may include interstitial lung disease, hypertension and pancreatitis. Therefore, when treating with brigatinib, doctors need to closely monitor the patient's response and adjust the dose or perform other interventions as needed.